UNCY
Price:
$0.37
Market Cap:
$34.91M
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.[Read more]
Industry
Biotechnology
IPO Date
2021-07-12
Stock Exchange
NASDAQ
Ticker
UNCY
According to Unicycive Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 3.37. This represents a change of 91.32% compared to the average of 1.76 of the last 4 quarters.
The mean historical Current Ratio of Unicycive Therapeutics, Inc. over the last ten years is 1.74. The current 3.37 Current Ratio has changed 19.26% with respect to the historical average. Over the past ten years (40 quarters), UNCY's Current Ratio was at its highest in in the September 2021 quarter at 25.20. The Current Ratio was at its lowest in in the March 2019 quarter at 0.
Average
1.74
Median
0.42
Minimum
0.02
Maximum
8.75
Discovering the peaks and valleys of Unicycive Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 12.23%
Maximum Annual Current Ratio = 8.75
Minimum Annual Increase = -90.79%
Minimum Annual Current Ratio = 0.02
Year | Current Ratio | Change |
---|---|---|
2023 | 0.76 | -5.09% |
2022 | 0.81 | -90.79% |
2021 | 8.75 | 12.23% |
2020 | 0.07 | 237.23% |
2019 | 0.02 | -10.39% |
The current Current Ratio of Unicycive Therapeutics, Inc. (UNCY) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
3.44
5-year avg
2.08
10-year avg
1.74
Unicycive Therapeutics, Inc.’s Current Ratio is greater than TransCode Therapeutics, Inc. (1.25), less than Ambrx Biopharma Inc. (12.80), less than Cardio Diagnostics Holdings, Inc. (5.69), greater than Hillstream BioPharma, Inc. (2.25), greater than SeqLL Inc. (1.06),
Company | Current Ratio | Market cap |
---|---|---|
1.25 | $12.09M | |
12.80 | $1.77B | |
5.69 | $5.44M | |
2.25 | $4.17M | |
1.06 | $185.31M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Unicycive Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Unicycive Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Unicycive Therapeutics, Inc.'s Current Ratio?
How is the Current Ratio calculated for Unicycive Therapeutics, Inc. (UNCY)?
What is the highest Current Ratio for Unicycive Therapeutics, Inc. (UNCY)?
What is the 3-year average Current Ratio for Unicycive Therapeutics, Inc. (UNCY)?
What is the 5-year average Current Ratio for Unicycive Therapeutics, Inc. (UNCY)?
How does the current Current Ratio for Unicycive Therapeutics, Inc. (UNCY) compare to its historical average?